It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

Spruce is racing financial and regulatory time in taking over development of TA-ERT from now-shuttered Allievex Corp., which originally licensed the program from San Rafael-based BioMarin (Nasdaq ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could expand BMRN's market in 2025.

StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating in a report issued on Tuesday. Other analysts also recently issued research ...

Palynziq significantly lowered blood Phe levels in adolescents vs. diet alone. BioMarin will submit data for label expansion to health authorities this year. The ‘Trade of the Day’ is now live. Get a ...

A month has gone by since the last earnings report for BioMarin Pharmaceutical (BMRN). Shares have added about 4.2% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...